Adaptyv Secures $40M: Automated AI Lab Reshapes Drug Discovery
August 28, 2026, 3:31 pm
Location: United States, California, South San Francisco
Employees: 10001+
Founded date: 1896
Location: United States, California, Mountain View
Employees: 51-200
Founded date: 2005
Adaptyv secures $40 million in Series A funding. This investment builds an automated AI lab. It tackles a critical bottleneck in drug discovery. AI now designs thousands of protein molecules quickly. Traditional labs cannot test them at this scale. Adaptyv’s platform bridges this gap. It offers "agentic biology." This means AI designs, tests, and learns autonomously. No human intervention is needed. Cell-free protein production drives this innovation. This funding fuels massive expansion. It triples lab capacity. It opens a London office. Adaptyv becomes a key player in the future of medicine. It pushes boundaries in protein engineering.
The future of drug discovery accelerates. Adaptyv, a Swiss biotech firm, just secured a $40 million Series A round. This significant capital injection targets a crucial chasm. It will build an automated AI lab. This facility revolutionizes how new medicines are found.
AI has transformed protein design. Tools like AlphaFold and Boltz generate thousands of candidates. This happens in mere hours. The challenge arises next. Traditional wet labs cannot keep pace. They were built for different times. They handle perhaps 20 designs. Not thousands. This creates a massive bottleneck. AI's speed is wasted.
Adaptyv directly addresses this inefficiency. It constructed an "AI-native lab." This automated system closes the loop. It connects AI design with experimental validation. The process is seamless. It moves from digital sequence to lab data. No human touches a pipette.
Core to Adaptyv's approach is cell-free protein production. This method is highly efficient. It uses only necessary biochemical machinery. It turns DNA into protein. Living cells are bypassed. This dramatically speeds up the testing process.
What makes Adaptyv truly groundbreaking is its agentic biology platform. An API is central to this. AI agents can design a protein. They send the order to Adaptyv’s lab. They receive results back. They then use this data. They design the next round of experiments. All this happens autonomously. Human intervention is removed.
The API is already integrated. Leading AI tools connect directly. Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling are among them. This fosters a collaborative ecosystem. AI models can learn and improve faster.
This technological leap holds immense promise. It slashes drug discovery timelines. It reduces development costs. It allows for unprecedented scale in experimentation. Potential drug candidates are validated quicker. Failed designs are discarded rapidly. This iterative cycle accelerates innovation.
Highland Europe led the $40 million Series A. Existing investors doubled down. Ace Ventures, ByFounders, and Y Combinator showed continued confidence. Ace Ventures previously led an $8 million Seed round in late 2024. They recognized Adaptyv's potential early. They saw the solution to the AI-lab validation gap.
Adaptyv's growth plans are ambitious. The new funding fuels three key priorities. First, increased automated lab infrastructure. This boosts throughput dramatically. It supports more designs, faster results. The company plans to triple lab capacity by year-end 2026.
Second, the team will expand. Adaptyv plans to double its Lausanne team. Headcount will rise from 25 to around 60. This supports burgeoning customer demand. It ensures faster turnaround times.
Third, global expansion is underway. A new office and lab will open in London. This is slated for Q4 2026. Proximity to European pharma giants is a strategic move. It brings Adaptyv closer to major AI customers.
Beyond infrastructure, Adaptyv invests in community. It launched Proteinbase. This is a competition platform. It attracted 680 participants. It generated 10,000 protein designs. The goal is clear. Crowdsource difficult protein problems. Generate more public training data. This benefits the entire field.
Adaptyv is also broadening its scope. It expands beyond protein binding assays. New areas include developability studies. Biophysical characterization is another focus. Next-generation modalities are also on the roadmap. This indicates a wider application of its platform.
The company's vision extends far. Its long-term ambition is a "biological gigafactory." Here, AI learns from physical experiments. This learning occurs as quickly as it learns from text data. It’s a future where biological design is instantly validated.
Switzerland positions itself as a biotech hub. Over 55 VC-backed TechBio startups call it home. Lausanne and Zurich are particular hotspots. They concentrate AI-driven protein engineering companies. Adaptyv aims to be the default lab backend for this ecosystem.
Leading pharmaceutical companies already partner with Adaptyv. Roche and Novo Nordisk are among its over 100 customers. Bio-AI companies like Chai Discovery and Boltz also leverage the platform. This demonstrates strong industry adoption. Adaptyv has increased lab throughput more than fivefold in the past year. This further validates its approach.
The funding round is more than just capital. It's a statement. It declares a new era for AI in biology. Adaptyv builds the infrastructure layer. It makes autonomous AI-driven experimentation real. The future of medicine depends on such innovation. Faster, more efficient drug discovery is now within reach.
The future of drug discovery accelerates. Adaptyv, a Swiss biotech firm, just secured a $40 million Series A round. This significant capital injection targets a crucial chasm. It will build an automated AI lab. This facility revolutionizes how new medicines are found.
AI has transformed protein design. Tools like AlphaFold and Boltz generate thousands of candidates. This happens in mere hours. The challenge arises next. Traditional wet labs cannot keep pace. They were built for different times. They handle perhaps 20 designs. Not thousands. This creates a massive bottleneck. AI's speed is wasted.
Adaptyv directly addresses this inefficiency. It constructed an "AI-native lab." This automated system closes the loop. It connects AI design with experimental validation. The process is seamless. It moves from digital sequence to lab data. No human touches a pipette.
Core to Adaptyv's approach is cell-free protein production. This method is highly efficient. It uses only necessary biochemical machinery. It turns DNA into protein. Living cells are bypassed. This dramatically speeds up the testing process.
What makes Adaptyv truly groundbreaking is its agentic biology platform. An API is central to this. AI agents can design a protein. They send the order to Adaptyv’s lab. They receive results back. They then use this data. They design the next round of experiments. All this happens autonomously. Human intervention is removed.
The API is already integrated. Leading AI tools connect directly. Boltz, Chai, Cradle, Tamarind, Latent Labs, and Benchling are among them. This fosters a collaborative ecosystem. AI models can learn and improve faster.
This technological leap holds immense promise. It slashes drug discovery timelines. It reduces development costs. It allows for unprecedented scale in experimentation. Potential drug candidates are validated quicker. Failed designs are discarded rapidly. This iterative cycle accelerates innovation.
Highland Europe led the $40 million Series A. Existing investors doubled down. Ace Ventures, ByFounders, and Y Combinator showed continued confidence. Ace Ventures previously led an $8 million Seed round in late 2024. They recognized Adaptyv's potential early. They saw the solution to the AI-lab validation gap.
Adaptyv's growth plans are ambitious. The new funding fuels three key priorities. First, increased automated lab infrastructure. This boosts throughput dramatically. It supports more designs, faster results. The company plans to triple lab capacity by year-end 2026.
Second, the team will expand. Adaptyv plans to double its Lausanne team. Headcount will rise from 25 to around 60. This supports burgeoning customer demand. It ensures faster turnaround times.
Third, global expansion is underway. A new office and lab will open in London. This is slated for Q4 2026. Proximity to European pharma giants is a strategic move. It brings Adaptyv closer to major AI customers.
Beyond infrastructure, Adaptyv invests in community. It launched Proteinbase. This is a competition platform. It attracted 680 participants. It generated 10,000 protein designs. The goal is clear. Crowdsource difficult protein problems. Generate more public training data. This benefits the entire field.
Adaptyv is also broadening its scope. It expands beyond protein binding assays. New areas include developability studies. Biophysical characterization is another focus. Next-generation modalities are also on the roadmap. This indicates a wider application of its platform.
The company's vision extends far. Its long-term ambition is a "biological gigafactory." Here, AI learns from physical experiments. This learning occurs as quickly as it learns from text data. It’s a future where biological design is instantly validated.
Switzerland positions itself as a biotech hub. Over 55 VC-backed TechBio startups call it home. Lausanne and Zurich are particular hotspots. They concentrate AI-driven protein engineering companies. Adaptyv aims to be the default lab backend for this ecosystem.
Leading pharmaceutical companies already partner with Adaptyv. Roche and Novo Nordisk are among its over 100 customers. Bio-AI companies like Chai Discovery and Boltz also leverage the platform. This demonstrates strong industry adoption. Adaptyv has increased lab throughput more than fivefold in the past year. This further validates its approach.
The funding round is more than just capital. It's a statement. It declares a new era for AI in biology. Adaptyv builds the infrastructure layer. It makes autonomous AI-driven experimentation real. The future of medicine depends on such innovation. Faster, more efficient drug discovery is now within reach.